One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis

Toru Inoue, Kazuyuki Numakura, Takahiro Osawa, Sei Naito, Takuma Ishihara, Kojiro Ohba, Kosuke Ueda, Yuya Sekine, Masaharu Oki, Hirohito Naito, Haruka Miyata, Hiroshi Kikuchi, Shin Kobayashi, Shintaro Narita, Norihiko Tsuchiya, Mikio Sugimoto, Tsukasa Igawa, Toshitaka Shin

Open source

DOI: 10.1007/s11523-026-01251-y
Published: 2026-09-14
Container: Targeted Oncology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s11523-026-01251-y,
  title = {One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis},
  author = {Toru Inoue and Kazuyuki Numakura and Takahiro Osawa and Sei Naito and Takuma Ishihara and Kojiro Ohba and Kosuke Ueda and Yuya Sekine and Masaharu Oki and Hirohito Naito and Haruka Miyata and Hiroshi Kikuchi and Shin Kobayashi and Shintaro Narita and Norihiko Tsuchiya and Mikio Sugimoto and Tsukasa Igawa and Toshitaka Shin},
  year = {2026},
  journal = {Targeted Oncology},
  doi = {10.1007/s11523-026-01251-y},
  url = {https://doi.org/10.1007/s11523-026-01251-y}
}

RIS

TY  - JOUR
TI  - One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis
AU  - Toru Inoue
AU  - Kazuyuki Numakura
AU  - Takahiro Osawa
AU  - Sei Naito
AU  - Takuma Ishihara
AU  - Kojiro Ohba
AU  - Kosuke Ueda
AU  - Yuya Sekine
AU  - Masaharu Oki
AU  - Hirohito Naito
AU  - Haruka Miyata
AU  - Hiroshi Kikuchi
AU  - Shin Kobayashi
AU  - Shintaro Narita
AU  - Norihiko Tsuchiya
AU  - Mikio Sugimoto
AU  - Tsukasa Igawa
AU  - Toshitaka Shin
PY  - 2026
JO  - Targeted Oncology
DO  - 10.1007/s11523-026-01251-y
UR  - https://doi.org/10.1007/s11523-026-01251-y
ER  -

APA

Inoue, T., Numakura, K., Osawa, T., Naito, S., Ishihara, T., Ohba, K., Ueda, K., Sekine, Y., Oki, M., Naito, H., Miyata, H., Kikuchi, H., Kobayashi, S., Narita, S., Tsuchiya, N., Sugimoto, M., Igawa, T., & Shin, T. (2026). One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis. Targeted Oncology. https://doi.org/10.1007/s11523-026-01251-y

Source records

crossref · retrieved 2026-09-26T09:00:42.971Z